Taking Charge of the Skin You’re In: 3 Levels of Melanoma Prevention and Detection

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 3 April 2017 In Melanoma Stories, Prevention, Treatment

No healthy person in their twenties expects they’re going to get a call one day telling them they have an invasive nodular melanoma. Despite seeing and hearing of horrible stories about young patients developing cancers, we can’t imagine it’ll happen to us. That element of surprise is exactly what 25-year-old medical student, Alissa Prior, experienced upon hearing her diagnosis.

Read More


Finance Industry Rallies to Fight Melanoma

By Rachel Gazzerro, MRA Associate Director, Development & Information Management | 3 April 2017 In Allies & Partnerships, Events

Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event, sponsored annually in New York City by the Melanoma Research Alliance (MRA) has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities – all gathered together in response to melanoma.

Read More


Polka Dot Mama Melanoma Foundation Launches Shade Shuttle Bus Tour

By Pamela Goldsmith, MRA Director of Communications | 2 April 2017

Taking her advocacy to the next level, Tracy Callahan, along with the Tara Miller Melanoma Foundation, is about to launch Shade Shuttle, a multi-state bus tour dedicated to raising awareness and educating the community about melanoma.

Read More


MRA Researchers in the News

20 January 2017 In News

• Disabling Critical "Node" Revs Up Attack When Cancer Immunotherapies Fall, Short, Healthcanal.com, 12/1/2016

• Blood protein may help doctors determine which patients are likely to benefit from immune checkpoint inhibitors, Healthcanal.com,12/22/2016
...

Read More


Spotlight on MRA’s Ninth Annual Scientific Retreat

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 February 2017 In Allies & Partnerships, Events, Science

In mid-February, MRA held its premiere research event — the 9th Annual Scientific Retreat, in Washington, DC. A total of 297 individuals registered for the meeting representing a spectrum of key stakeholders in melanoma including academic investigators, pharmaceutical and biotech company representatives, melanoma advocates from various different non-profit organizations, donors and government officials.

Read More


Melanoma Prevention: The Latest Advances & Future Directions

By Pamela Goldsmith, MRA Director of Communications | 28 February 2017 In Events, Policy, Prevention, Science

During my interview with Susan Swetter, MD, Professor of Dermatology,
Stanford University and VA Palo Alto, at the Melanoma Research Alliance Ninth Annual Scientific Retreat in Washington, DC, I inquired about the Panel Discussion she was part of titled: News from the field: What’s going well and what remains to be done?

Read More


MRA’s Young Investigator Program: Bringing New Talent & Novel Ideas for Research Forward

By Pamela Goldsmith, MRA Director of Communications | 28 February 2017 In Events, Science

In February, at the Ninth Annual MRA Scientific Retreat, a Young Investigator Breakfast brought together scores of past and current MRA Young Investigators where I connected with one of MRA’s first young investigators, Dr. Timothy Bullock.

Read More


The Power of Combination Therapies: One Patient’s Road to Remission

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 28 February 2017 In Science, Treatment

Metastatic melanoma can be a devastating diagnosis to receive. Just hearing the word cancer for most is terrifying. While the fear is understandable, today new targeted therapies and immunotherapies are delivering new hope for many.

Read More


Melanoma 2016 — the Year in Review

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 20 January 2017 In News

In the nearly 10 years since MRA’s founding in 2007, there has been extraordinary progress for melanoma. With 11 new treatments approved since 2011, it began to feel like frequent new drug approvals was the current norm.

Read More


Understanding Neoantigens: A Critical Target for Improving Immunotherapy

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 20 January 2017

The approval of eleven new therapies for melanoma since 2011 has led to dramatic changes in how doctors treat melanoma and even more importantly, has led to better outcomes for many patients. Chief among the new therapies are those that target the immune system.

Read More


Login

×